NCT04485260

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Kartos Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of the study is to determine a recommended phase 2 dose (RP2D) of KRT 232 in combination with ruxolitinib.

Conditions

• Myelofibrosis

Interventions

Type	Name	Description
DRUG	KRT-232	administered by mouth
DRUG	Ruxolitinib	administered by mouth

Timeline

• Start date: 2021-01-28
• Primary completion: 2022-10-01
• Completion: 2024-10-01
• First posted: 2020-07-24
• Last updated: 2022-05-09

Locations

38 sites across 9 countries: United States, Australia, Bulgaria, France, Germany, Israel, Italy, Poland, Spain

Regulatory

• FDA-regulated drug study